KMT Hepatech Announces Expansion of Staff and Operations in Edmonton
EDMONTON, Alberta--(21 December 2017) -- KMT Hepatech, Inc. (“KMT”), a part of PhoenixBio group, announced plans to expand staff and operations by providing services with PXB-Mouse® and starting the production of the PXB-Cells® – hepatocytes isolated from cDNA-uPA/SCID mice with highly humanized liver. The isolated fresh hepatocytes (PXB-Cells®) will be supplied to the clients to support researchers across a wide range of drug development fields, including hepatitis B (HBV) in vitro studies and DMPK research.
PXB-Mouse® is a chimeric mouse with more than 70% of the liver replaced with normal human hepatocytes. The uPA/SCID mouse model with a highly humanized liver was first on the market and has been the most utilized mouse model since 2001.